PrevANZ Vitamin D MS Prevention Trial
Update November 2018
PrevANZ is a world-first clinical trial that will test whether oral vitamin D supplementation can prevent MS in those at high risk of developing the disease.
Funded by MS Research Australia with the support of many generous donors, including the Trish MS Research Foundation, this gold-standard clinical trial aims to resolve the unanswered question of whether vitamin D supplementation is effective to prevent a diagnosis of MS following a person’s first clinical ‘attack’ suggestive of MS.
This is an area in which the expertise in Australia and New Zealand is second to none and PrevANZ represents an unequaled opportunity to have a major impact in the prevention and better treatment of MS globally.
The trial has now enrolled 179 participants, a milestone of 75% of the target of 240. All aspects of patients’ participation in the trial are running smoothly, with no safety concerns currently emerging. As a ‘double-blind’ trial where doctors and patients are unaware of the dose delivered to each patient, it is not yet possible to provide any early indication of the effects of vitamin D supplementation.
The PrevANZ team are continuing to work closely with the medical community to promote the ongoing trial and maximise recruitment for a successful conclusion to the trial with results anticipated in 2020.